ProKidney Corp - Ordinary Shares - Class A
NASDAQ:PROK 2:04:53 PM EDT
| Market Cap (Intraday) | 357.72M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.50 |
| 50-Day MA | $2.78 |
| 200-Day MA | $1.61 |
ProKidney Corp - Ordinary Shares - Class A Stock, NASDAQ:PROK
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, North Carolina 27103
United States of America
Phone: +1.336.999.7028
Number of Employees: 163
Description
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.